These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37926852)

  • 21. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis.
    Zhang C; Wei F; Ma W; Zhang J
    Front Immunol; 2024; 15():1255825. PubMed ID: 38318172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis.
    Huo G; Liu W; Zhang S; Chen P
    Immunotherapy; 2023 Feb; 15(3):189-207. PubMed ID: 36683533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
    Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
    Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicities associated with immune checkpoint inhibitors: a systematic study.
    Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
    Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review.
    Galle P; Finn RS; Mitchell CR; Ndirangu K; Ramji Z; Redhead GS; Pinato DJ
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38238030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis.
    Jin C; Zhu X; Huang X; Gong T; Wei Z; You J
    J Comp Eff Res; 2022 Feb; 11(3):203-212. PubMed ID: 35023361
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
    Nie RC; Zhao CB; Xia XW; Luo YS; Wu T; Zhou ZW; Yuan SQ; Wang Y; Li YF
    Biomed Res Int; 2020; 2020():5059079. PubMed ID: 32461994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.
    Qian D; Xu Y; Wu Y; Qiu J; Hong W; Meng X
    Chin Med J (Engl); 2023 Jul; 136(14):1663-1670. PubMed ID: 37279392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.
    Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
    Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
    Li H; Xu J; Bai Y; Zhang S; Cheng M; Jin J
    Invest New Drugs; 2021 Jun; 39(3):860-870. PubMed ID: 33409896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
    Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A
    J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.